MetaCap

Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs SciSparc (SPRC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($982,950 vs $481,603), about 2.0 times the size. On valuation, SciSparc trades at a lower trailing P/E (0.0x vs 0.0x for Biodexa Pharmaceuticals American Depositary Shs).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDRX+232.56%SPRC-95.79%
+671%+269%-132%
Oct 7, 20261 yearNov 20, 2026
BDRX+307.43%SPRC-95.63%
+682%+275%-133%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDRX versus SPRC key metrics
MetricBDRXSPRC
Share price$1.88$0.1955
Market cap$982.95K$481.60K
1-day change-3.85%-34.83%
P/E ratio (TTM)0.000.00
EPS (TTM)$509.89$248.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.31M
Revenue growth (YoY)—-54.64%
Net income (latest FY)—$-6.28M
Gross margin—38.74%
Operating margin—-560.18%
Net margin—-481.16%
52-week high$357.60$29.88
52-week low$1.85$0.167
Distance from 52-week high-99.48%-99.35%
Analyst consensusnone—
Avg. price target upside+375.20%—
Average volume618.91K2.93M
Shares outstanding524.24K2.46M
Employees113
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Biodexa Pharmaceuticals American Depositary Shs is about 2.0 times larger than SciSparc by market value ($982.95K vs $481.60K).
  • Biodexa Pharmaceuticals American Depositary Shs trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).

About Biodexa Pharmaceuticals American Depositary Shs

BDRX stock →

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About SciSparc

SPRC stock →

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

BDRX vs SPRC FAQ

Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or SciSparc?

Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $982.95K compared with $481.60K for SciSparc (SPRC).

Which has the lower P/E ratio, BDRX or SPRC?

SPRC has the lower trailing P/E at 0.0, versus 0.0 for BDRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Biodexa Pharmaceuticals American Depositary Shs and SciSparc in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons